Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL

NCT06764238 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06764238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06764238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 3, 2025
Completion date
June 30, 2031
Enrollment
1,800 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia all, b cell acute lymphoblastic leukemia (b-all), childhood leukemia, acute lymphoblastic